28/06/2023 - General information
The Mutua Madrileña Foundation has awarded its XX Health Research Grants, worth 2.3 million euros, to 26 clinical studies that will be carried out in hospitals throughout Spain. Six of these research projects will be carried out in Barcelona in the areas of cancer immunotherapy, rare childhood diseases, infant and juvenile mental health and transplantation, and together receive funding of more than 680,000 euros. From the Hospital del Mar Research Institute, Doctor Joaquín Arribas, will carry out a study in the field of immunotherapy in cancer. Specifically, it will perform a prospective analysis of biopsies obtained in a phase 1 clinical trial of dose increase using CAR-t Her 2 biospecific cells in patients with advanced solid tumors positive for P95HER2.
07/11/2022 - General information
At the same time, the head of the Haematological Cytology section of the Pathology Service of the Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute, is secretary of the board of directors of the Spanish Group for Haematological Cytology and also holds the same position in the Spanish Group of Myelodysplastic Syndromes.
24/10/2022 - General information
Two of the grants are awarded by SEOM itself and the third by the Spanish Lung Cancer Group. Two research projects from the Hospital del Mar and the Hospital del Mar Medical Research Institute have received three grants of support during the congress of the Spanish Society of Medical Oncology, held in Madrid from October 18 to 21. The two projects will analyze different aspects related to immunological markers in different subtypes of lung cancer and in patients with different behaviors in response to immunotherapy.
20/10/2022 - General information
Ramon Diez-Feijóo Varela and Sílvia Ramos Campoy have received two personal grants to develop different research projects. Two researchers from the Hospital del Mar and the Hospital del Mar Medical Research Institute have received two grants from the Spanish Society of Hematology and Hemotherapy, within the framework of the LXIV congress of the organization, held in Barcelona from October 6 to 8. These are personal grants for one year, worth 36,000 euros, renewable for a second year.
23/08/2022 - General information
A team from Hospital del Mar and the Hospital del Mar Medical Research Institute has validated the technique involving breast biopsy guided by contrast mammography to visualise suspicious lesions that cannot be observed via ultrasound or mammography. After analysing data from tests performed on 64 women, they have been able to verify that this technique offers the same or better results than the other diagnostic tool used in these cases, magnetic resonance imaging (MRI). The results have been published in the journal European Radiology. In the cases studied, contrast mammography-guided breast biopsy was successful in 95.4% of cases. In only three tests was the visibility of the findings not as expected. In comparison, MRI has a success rate of between 87% and 98%.
Més informació "Usefulness of breast biopsy guided by contrast-enhanced mammography is validated"
12/07/2022 - General information
This is one of the fifteen biomedical projects selected in the CaixaResearch Validate call. In this case, the study led by the researcher from the Hospital del Mar Medical Research Institute seeks effective immunotherapy treatment for breast tumours. The "la Caixa" Foundation is supporting 15 leading biomedical research projects in Spain and Portugal in the CaixaResearch Validate 2022 call. These are early-stage projects that the organisation wants to support to accelerate their arrival on the market, thereby helping them reach patients who may need them. Among those selected is a project led by Dr. Toni Celià-Terrassa, who heads up the Cancer Stem Cells and Metastasis Dynamics laboratory at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar).
31/03/2022 - General information
The project "Tumour microenvironment-derived factors in localised colon cancer: clinical impact and therapeutic implications' (TuMiCC)"aimed at demonstrating the value of the tumour microenvironment in predicting relapse in patients with localised colon cancer treated with adjuvant therapy, has reached the 16-month development milestone, with patient recruitment and interesting advances in the molecular characterisation of this type of tumour and its environment.
17/02/2022 - General information
An IMIM-Hospital del Mar research project aimed at analyzing the mechanisms that generate resistance to immunotherapy treatment in metastatic breast cancer has been selected by the Metastatic Breast Cancer Association in the third edition of this award. The project, headed by doctors Toni Celià-Terrassa and Joan Albanell, will receive 100,000 euros for its development. This afternoon saw the presentation of the III M. Chiara Giorgetti Award for research into metastatic breast cancer. This year it recognises a project from the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), led by doctors Toni Celià-Terrassa and Joan Albanell. The award is promoted by the Metastatic Breast Cancer patients' association and involves a prize of 100,000 euros, 25,000 euros of which are provided by the AMAMA association.
Més informació "M. Chiara Giorgetti Award for a Hospital del Mar Medical Research Institute project"
31/01/2022 - General information
Glioblastoma and oral drugs for various types of cancer are among the targets of the projects for the first phase, selected from among more than a hundred proposals, due to their clinical and industrial relevance The project "PARP2: a new therapeutic target in c-myc-driven tumours", headed up by Dr. José Yélamos, coordinator of the Poly (ADP-ribose) polymerase research group at the Hospital del Mar Medical Research Institute (IMIM) and the Immunology Service at Hospital del Mar, has been selected in the first edition of the Cancer Innova initiative, a consortium comprising the Kaertor Foundation and the Spanish Association Against Cancer in collaboration with the pharmaceutical companies Janssen and Lilly, which is supported by the Galician regional government. On this occasion, 110 proposals from eight countries were submitted, of which just five were selected based on their high clinical and industrial impact.
26/01/2022 - General information
The technique achieves good results in terms of toxicity, the preservation of the physical appearance and patient ratings when used for partial breast irradiation compared to its use in combination with large doses of fractionated whole-breast irradiation. Patients with early-stage breast cancer more positively evaluate treatment with partial intraoperative radiotherapy of the breast than the approach that uses the same technique in combination with whole-breast irradiation divided into large doses. This is highlighted in a study published in the journal Clinical and Translational Oncology, led by the Radiation Oncology Service and the Functional Breast Pathology Unit at Hospital del Mar as well as researchers in the Radiation Oncology Research Group at the Hospital del Mar Medical Research Institute.
Més informació "Partial intraoperative radiotherapy in breast cancer, more highly rated by patients"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
